Key result
Despite the availability of effective antihypertensive therapies, blood pressure control remains poor globally due to patient noncompliance, physician inertia, and healthcare system shortcomings.
Answers are grounded in this paper and cite their sources.
This editorial emphasizes the urgent need for multifaceted actions involving patients, physicians, and healthcare systems to address the globally high prevalence of uncontrolled hypertension.
Great progress has been made during, the last 50 years, in our attempts to control blood pressure (BP) in the population and in particular in hypertensive patients [1]. First, physicians noticed that very strict control of salt intake was able to decrease BP significantly even in so-called malignant hypertension; this was followed by a continuous search to finding antihypertensive drugs: different classes were detected each having a specific mechanism; careful well designed controlled studies have proven their efficacy. Recently, new techniques have been developed like renal nerve ablation [2] and stimulation of baroreceptors [3]. Logically, it was to be expected that all these tools along with lifestyle adaptation and decrease of salt consumption, could have induced an almost complete control of high BP and its consequences on the cardiovascular, renal, and cerebral system. Indeed, hypertension is considered not only as a very important risk factor but also a risk factor that can be controlled perfectly well. Surprisingly, the reality is quite different from what might be expected. In 2010, the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice study [4], setup to investigate the status of primary cardiovascular prevention, concluded that less than 40% of hypertensive patients achieved target BP. Thus, almost 60% were not or incompletely controlled. True, the results are different from country to country [5], but overall the situation has become a great matter of concern and lead to the publication of a fact sheet by WHO and the International Society of Hypertension [6]. In a recent study published in this Journal by Yusufali et al.[7] BP control was analyzed in 52 urban and 35 rural communities living in four countries of the Middle East. From 10 516 participants in the study, with a mean age of around 50 years, 3270 were found to be hypertensive; only 47% were on treatment and worse, only 19% had reached target BP. Although the study was cross-sectional without long-term follow-up and information on life-style control was partly incomplete, this interesting study clearly informed us that the problem of poor BP control is also highly prevalent in Middle East countries. How to explain that the very effective tools to lower BP that we have in hand do not result in better control in real life? Before all, let us not be excessively negative. In Europe, trends in a good direction have been published [8]; in US, recently, data on 9255 adults participating in the National Health and Nutrition Examination Survey 2003–2012 were published [9]. Among patients taking antihypertensive medication, uncontrolled hypertension decreased from 38 to 30%. Such results do illustrate that actions indeed help; however, we should continue and not accept that such a large proportion of hypertensive patients remain uncontrolled and thus at high risk. ACTION IS MORE THAN NECESSARY A number of possibilities have been suggested and discussed at congresses worldwide; we summarize some of these in the lines below. The finger is often pointed at patients for their noncompliance to antihypertensive treatment; inertia of physicians is another issue; the role of healthcare systems should also be questioned. Patients’ low compliance to treatment Patients dislike to take antihypertensive drugs; they very often have no or minimal symptoms linked to high BP; however, they often declare a decrease in quality of life especially at the start of treatment. Understandably, they question whether this is the way to continue. As a consequence, many stop treatment when BP seems to have come to or close to target; in their view, from that moment, their problem of high BP is ‘cured’. The low adherence gets even more pronounced as soon as more than one pill a day has to be taken, which often is the case with the actual trends to combination therapy. Also, one should realize that long-term treatment with antihypertensive drugs bears a nonnegligible cost. Adaptation of lifestyle and salt intake is strongly advocated by physicians, sometimes with abundant illustrations in the press; however, it all looks appealing in the beginning of the treatment but often is discontinued afterwards. Inertia of physicians This is the condition whereby the physician indeed realizes that the BP is too high but does not take action. Physicians rightly realize that BP can be increased while seeing a doctor and assume, unfortunately without proof, that pressure is much lower in normal life. Yes, white-coat hypertension is well known and accepted as a real entity but to be true, it needs to be investigated and objectively confirmed; moreover, even white-coat hypertension may well be less innocent than initially thought. That the role of physicians is not optimal was recently shown by the findings of the Euro-Aspire study [10]. This interesting study analyzed the evolution of risk factors in patients who suffered from a serious cardiovascular or other event and thus are at high risk for a new event; most surprisingly the investigators detected in the follow-up of such patients, that there is by far no perfect control of their BP. Even worse, there is no trend towards the good direction in the years afterwards. Role of healthcare systems It is clear that to control a problem in the population with a prevalence of up to 50%, healthcare systems should put hypertension at the highest level on their agenda. This is often not the case. Sometimes the costs of treatment are highlighted without underlining that treatment can prevent dangerous complications such as heart failure or stroke and that these, besides the social tragedy elicited by the disease, cost financially even more to the community. What should we do? No doubt, action should be taken on all possible levels and all priority should be given to such action [5]. Let us follow possible actions on the issues mentioned above. This does by no means exclude the need to impact on all other scientifically and ethically proven items that can help solving the problem. In this respect, also the pharmaceutical industry can help us in a number of aspects. Patients – and their family – should be informed better on the risk of uncontrolled high BP. Awareness of the prevalence of hypertension and its consequences needs to be strongly increased. As done in the past, BP measurement sessions should be reorganized to inform patients – and the whole population – on their BP and the risks of hypertension; furthermore, explanation should be given on the efficacy of high BP prevention and the beneficial effects of treatment to prevent those complications. In a number of hypertensive patients, home BP recordings can be ordered to unmask the ‘real’ BP to patients and their physicians. The help of pharmacists and nurses would be most welcome and newer technologies such as the use of App's, Telemedicine, are promising. Physicians should have clear and objective scientific information at hand concerning the risks their hypertensive patients run. Understandably, physicians devote more time to patients who are more symptomatic; however, this automatically puts the asymptomatic hypertensive patient in the ‘forgotten corner’ and this is part of the problem. Great attention should be given to secure correct measurement of BP. It is very informative to measure BP repeatedly, for example, three times in the same body position using a validated monitor. Ambulatory BP recordings do help a lot in offering an objective picture of the 24-h BP in real life including during the night. One should not forget the better correlation of ambulatory BP to events [11]. An easy method to see how far sufficient attention has been devoted to BP in clinical practice, is to keep a daily record of all values measured during the day and to question at the end of the day, what action has been taken for the excessive figures in the list. Clinical experience has shown that by doing so, many more uncontrolled values are detected that would remain unchanged without doing this simple check. It is evident that healthcare instances should help us at local, national, and EU level, to get this problem solved. In this respect, recently a ‘Thematic Federation on Hypertension’ was set up by the European Union of Medical Specialists to bring this problem to the attention of all doctors. Evidently, general practitioners are the first to see this type of patients; their help in the detection of hypertensive patients and their further management is of the greatest primary importance. But also all specialists should feel concerned and not only internists, cardiologists, nephrologists, or endocrinologists; awareness and solution of the present problem could come closer in case patients who consult a physician for whatever reason, would get a BP check. EU authorities should stimulate and offer facilities to such actions; at the same time, they will get informed on the almost unbelievable contradiction of having all tools in one hand to get a problem easily solved and on the other hand, not getting it done. ACKNOWLEDGEMENTS The author wants to thank Mrs Linda Packet for her valuable help in typing this article. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Denis L Clement (2017) conducted an editorial in Hypertension. Despite the availability of effective antihypertensive therapies, blood pressure control remains poor globally due to patient noncompliance, physician inertia, and healthcare system shortcomings.
Synapse has enriched 10 related papers. Consider them for comparative context: